MRVI (Maravai LifeSciences Holdings) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRVI Maravai LifeSciences Holdings Inc MRVI
58 GF Score
Price $6.97
GF Value $3.85
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Maravai LifeSciences Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Maravai LifeSciences Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1.1 Mil. Maravai LifeSciences Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $175.6 Mil. Maravai LifeSciences Holdings's annualized EBITDA for the quarter that ended in Jun. 2026 was $-14.3 Mil. Maravai LifeSciences Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -12.32.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Maravai LifeSciences Holdings's Debt-to-EBITDA or its related term are showing as below:

MRVI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.16   Med: 0.96   Max: 10.22
Current: -3.16

During the past 8 years, the highest Debt-to-EBITDA Ratio of Maravai LifeSciences Holdings was 10.22. The lowest was -3.16. And the median was 0.96.

MRVI's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs MRVI: -3.16

Maravai LifeSciences Holdings  (NAS:MRVI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Maravai LifeSciences Holdings Debt-to-EBITDA Related Terms

Maravai LifeSciences Holdings Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Maravai LifeSciences Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maravai LifeSciences Holdings Debt-to-EBITDA Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial - - - - -

Maravai LifeSciences Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MRVI vs GLUE, KURA, ODTX: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Maravai LifeSciences Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maravai LifeSciences Holdings Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's Debt-to-EBITDA falls into.


MRVI
58GF Score
Maravai LifeSciences Holdings Inc MRVI
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maravai LifeSciences Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Maravai LifeSciences Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(14.201 + 350.507) / -147.51
=-2.47

Maravai LifeSciences Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.125 + 175.571) / -14.344
=-12.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?

Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued. The current stock price of $6.97 is trading 81% above its estimated GF Value™ of $3.85. GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.

Key valuation signals for MRVI:

  • Debt-to-EBITDA:
  • GF Value™: $3.85 vs. price of $6.97 (81% above fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maravai LifeSciences Holdings Business Description

Other Exchanges MAR:Germany
Address 10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
58GF Score

Get the complete analysis for MRVI

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.97
Price
$3.85
GF Value